HBM HEALTHCARE INVESTMENTS AG 
By Press Release
Zug, 6 January 2012
ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline
ChemoCentryx, the fourth largest private company in the
portfolio of HBM BioVentures, has licensed another drug
candidate to GlaxoSmithKline (GSK) under an existing
collaboration between the two companies. GSK has exercised
its option to obtain an exclusive license for the further
development and worldwide commercialization of CCX354. CCX354
is a phase II compound for the treatment of rheumatoid
arthritis, a severe, chronic inflammatory disease affecting
over 20 million people worldwide.
Under the terms of the transaction, ChemoCentryx will receive
an option exercise fee of USD 25 million and will be eligible
for further milestone payments and royalties. GSK will be
solely responsible for funding the further clinical
development and commercialization of CCX354 worldwide.
HBM BioVentures has invested USD 13.7 million in ChemoCentryx
and is with an ownership stake of 8% one of the company's
largest shareholders. The book value of the investment is USD
18.5 million and will not be changed in accordance with HBM
BioVentures' valuation principles, in spite of this positive
news.
CCX354 is already the second drug candidate from ChemoCentryx
licensed to GSK. In January
2010, the two companies closed a similar transaction for
CCX282-B, an investigational drug for the treatment of
inflammatory bowel diseases such as Crohn's disease.
ChemoCentryx has a number of additional products in
development, including three further drugs in clinical
development.
ChemoCentryx Inc., located in Mountain View (California),
develops orally administered drugs for inflammatory diseases
and other conditions, applying its proprietary platform for
chemokine-based therapeutics. GSK's exercise of this
second licensing option is another important milestone in the
validation of the company's drug discovery and
development platform. To find out more, visit the
ChemoCentryx website at www.chemocentryx.com.
Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com www.hbmbioventures.com
NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA
For further information, please contact Dr. Andreas Wicki,
CEO HBM BioVentures Ltd, tel.: +41 41
768 11 08, andreas.wicki@hbmbioventures.com.
HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
DisclaimerThis media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements
of US securities legislation.
HBM BioVentures LtdBundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com www.hbmbioventures.com
| distribué par | Ce noodl a été diffusé par HBM BioVentures AG et initialement mise en ligne sur le site http://www.hbmbioventures.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-06 18:19:44 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
| Documents associés | |
| ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline |
